MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

Status Completed

Clinical Trial Summary

Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Clinical Trial Description

MYL-1402O is a monoclonal antibody currently being developed by Mylan GmbH, as a proposed biosimilar to European Union and US licensed Avastin (hereafter referred to as Avastin), which is approved as first line treatment in combination with carboplatin and paclitaxel (CP) for patients with Stage IV unresectable, recurrent or metastatic nsNSCLC. This randomized equivalence study is designed to meet the global regulatory requirement for approval of a biosimilar product. For this study, both MYL-1402O and Avastin are considered investigational medicinal products (IMP). ;

Study Design

Related Conditions & MeSH terms

NSCLC Stage IV

Clinical Trial Details

NCT number	NCT04633564
Study type	Interventional
Source	Viatris Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	January 21, 2017
Completion date	November 22, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05543330` - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	Phase 1/Phase 2
Recruiting	`NCT04106180` - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05215548` - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting	`NCT04492969` - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting	`NCT04116918` - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated	`NCT03411473` - Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2
Recruiting	`NCT03564197` - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC	N/A
Not yet recruiting	`NCT06219317` - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	Phase 2
Not yet recruiting	`NCT04604470` - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting	`NCT04136535` - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Completed	`NCT06339554` - Alectinib-induced Endocrine Toxicity
Active, not recruiting	`NCT04549428` - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2